证券代码：301258 证券简称：富士莱 公告编号：2025-062 苏州富士莱医药股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）第五届董事会第四次会议 于 2025 年 11 月 10 日上午 10 时在公司会议室以现场与通讯表决方式召开，会议 通知于 2025 年 11 月 3 日以邮件、电话、书面等方式通知全体董事。本次会议应 出席董事 7 人，实际出席董事 7 人。本次会议由董事长钱祥云先生召集并主持， 公司高级管理人员列席了本次会议。会议的召集、召开及表决程序符合法律法规 及《公司章程》的有关规定。 一、议案审议情况 与会董事经过审议，以记名投票表决方式通过如下决议： （一）审议通过《关于部分募投项目增加建设内容、使用超募资金追加投 资额的议案》 公司本次对募投项目追加投入、调整内部投资结构事项，符合公司当前实际 和发展需要，有利于提高超募资金使用效率，符合《上市公司募集资金监管规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 ...

根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号—回购股份》及《公司章程》等相关规定，回购期间，公司应当在每个月 的前三个交易日内披露截至上月末的回购进展情况。现将公司截至上月末的回购 股份的进展情况公告如下： 截至 2025 年 10 月 31 日，公司通过股票回购专用证券账户以集中竞价交易 方式累计回购公司股份数量为 920,000 股，占公司目前总股本的 1.0036%，最高 成交价为 35.43 元/股，最低成交价为 33.88 元/股，使用资金总额为 31,944,850.00 元（不含交易费用）。公司实施回购符合相关法律法规及既定的回购股份方案。 二、其他说明 公司回购股份的时间、回购股份价格及集中竞价交易的委托时段符合《深圳 证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定。 （一）公司未在下列期间回购公司股份： 证券代码：301258 证券简称：富士莱 公告编号：2025-061 苏州富士莱医药股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份 ...

Core Viewpoint - Fujilai's stock has shown significant growth this year, with a year-to-date increase of 52.95%, indicating strong market performance and investor interest [1][2]. Company Overview - Fujilai Pharmaceutical Co., Ltd. is located in Changshu, Jiangsu Province, and was established on November 27, 2000. The company went public on March 29, 2022, and specializes in the research, production, and sales of active pharmaceutical ingredients and health product raw materials [1]. - The main revenue sources for Fujilai include: 66.02% from alpha-lipoic acid products, 14.86% from carnosine products, 11.88% from etoricoxib, 5.95% from phosphatidylcholine products, and 1.29% from other supplementary products [1]. Financial Performance - For the period from January to September 2025, Fujilai achieved an operating income of 323 million yuan, representing a year-on-year growth of 3.23%. The net profit attributable to shareholders was 73.40 million yuan, showing a substantial increase of 430.16% [2]. - Since its A-share listing, Fujilai has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [3]. Shareholder Information - As of October 20, 2025, Fujilai had 11,000 shareholders, a decrease of 0.47% from the previous period. The average number of circulating shares per shareholder increased by 0.47% to 8,083 shares [2]. - Among the top ten circulating shareholders, Galaxy Kangle Stock A (519673) is the ninth largest, holding 178,100 shares as a new shareholder [3].

Core Viewpoint - Fujilai announced a stock buyback plan, indicating a commitment to returning value to shareholders and potentially signaling confidence in the company's future performance [1] Group 1 - As of October 31, 2025, the company has repurchased a total of 920,000 shares [1] - The repurchased shares represent 1.0036% of the company's current total share capital [1]

Core Viewpoint - Fujilai (301258.SZ) announced a share buyback program, indicating a commitment to returning value to shareholders and confidence in its financial health [1] Summary by Relevant Sections Share Buyback Details - The company has repurchased a total of 920,000 shares, which represents 1.0036% of its total share capital [1] - The highest transaction price during the buyback was 35.43 CNY per share, while the lowest was 33.88 CNY per share [1] - The total amount of funds used for the buyback was 31,944,850.00 CNY, excluding transaction fees [1] Compliance and Strategy - The share buyback is in accordance with relevant laws and regulations, as well as the established buyback plan [1]

证券代码：301258 证券简称：富士莱 公告编号：2025-060 苏州富士莱医药股份有限公司 关于回购公司股份比例达到 1%的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日召 开第五届董事会第二次会议，审议通过了《关于使用自有资金回购公司股份方案 的议案》，同意公司使用自有资金通过集中竞价交易方式回购公司人民币普通股 （A 股），并在未来适宜时机用于股权激励计划或员工持股计划。本次回购股份 资金总额不低于人民币 2,000 万元（含本数）且不超过人民币 4,000 万元（含本 数），回购价格不超过人民币 40.00 元/股（含）。回购期限自公司董事会审议通 过本次回购股份方案之日起不超过 12 个月。具体内容详见公司于 2025 年 10 月 14 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于使用自有资金回购公 司股份方案的公告》（公告编号：2025-053）。 一、回购股份进展情况 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监 ...

Group 1: Financial Performance - The company's net profit attributable to shareholders increased by 430.16% year-on-year in the first three quarters, but the non-recurring net profit was only 251.19 million yuan, indicating reliance on non-operating income for profit growth [2] - The total number of shareholders decreased by 9.16% compared to the end of the first half of the year, while the average market value per shareholding increased by 24.05%, indicating a rise in share concentration [3] - Cash and cash equivalents grew by 70.31% since the beginning of the year, primarily due to the maturity of financial products [3] Group 2: Business Strategy and Operations - The company plans to focus on the development of specialty APIs, pharmaceutical intermediates, and health product raw materials to enhance the contribution of its main business to profit growth [2] - The construction of the "Fujilai (Shandong) Specialty API and Intermediate CMO/CDMO Project" is expected to be completed by the end of June 2026, which will contribute to production capacity and revenue [4] - The gross profit margin for the third quarter decreased by 2.32 percentage points, attributed to a slight decline in the price of core product alpha-lipoic acid and reduced capacity utilization due to planned maintenance [3] Group 3: Market and Product Insights - The alpha-lipoic acid series accounts for 66.02% of the company's main revenue, but current market demand is weak due to significant price drops and inflation expectations overseas [4] - The company is optimizing its product line and expanding its market share for core products while also enhancing its product pipeline in response to the expiration of numerous innovative drug patents globally [2] Group 4: Shareholder and Investment Insights - The company holds 199,000 shares in its repurchase account, accounting for 2.17% of the total share capital, with plans to use these shares for employee stock ownership plans or stock incentives in the future [6] - The company will prioritize the efficient use of idle funds for financial management while ensuring liquidity and safety in its operations [3]

Core Insights - As of October 24, 616 companies have released their Q3 2025 reports, with 389 reporting a year-on-year increase in net profit, while 227 reported a decline [1] - 410 companies experienced a year-on-year increase in operating revenue, whereas 206 reported a decrease [1] - 317 companies saw both net profit and operating revenue increase, while 134 companies experienced declines in both metrics [1] - Notably, 92 companies had a net profit growth rate exceeding 100%, with Jingrui Electric Materials leading at an astonishing 19,202.65% [1] Financial Performance Summary - Jingrui Electric Materials (300655) reported earnings per share of 0.1212, net profit of 128.37 million, and a net profit increase of 19,202.65%, with operating revenue of 118.68 million, up 11.92% [1] - Xiaoming Co. (300967) had earnings per share of 0.9846, net profit of 183.06 million, and a net profit increase of 2,243.97%, with operating revenue of 102.41 million, up 58.98% [1] - New Strong Union (300850) reported earnings per share of 1.7800, net profit of 663.84 million, and a net profit increase of 1,939.50%, with operating revenue of 361.79 million, up 84.10% [1] - Other notable companies include Yinglian Co. (002846) with a net profit increase of 1,572.67% and TianNeng Heavy Industry (300569) with a net profit increase of 1,359.03% [1] Additional Company Highlights - Zhimin Da (688636) reported earnings per share of 0.4900, net profit of 81.99 million, and a net profit increase of 995.37%, with operating revenue of 51.16 million, up 145.16% [1] - Special One Pharmaceutical (002728) had earnings per share of 0.1300, net profit of 65.22 million, and a net profit increase of 985.18%, with operating revenue of 69.19 million, up 51.86% [1] - Wanchen Group (300972) reported earnings per share of 4.6840, net profit of 854.98 million, and a net profit increase of 917.04%, with operating revenue of 3,656.23 million, up 77.37% [1]

Core Viewpoint - Fujilai's stock price has experienced fluctuations, with a year-to-date increase of 49.68% and a recent decline of 2.00% on October 24, 2023, indicating volatility in market performance [1][2]. Financial Performance - For the period from January to September 2025, Fujilai reported a revenue of 323 million yuan, reflecting a year-on-year growth of 3.23%. The net profit attributable to shareholders reached 73.4 million yuan, showing a significant increase of 430.16% [3]. - Since its A-share listing, Fujilai has distributed a total of 153 million yuan in dividends, with 116 million yuan distributed over the past three years [4]. Stock Market Activity - As of October 20, 2023, Fujilai had 11,000 shareholders, a decrease of 0.47% from the previous period. The average number of circulating shares per shareholder increased by 0.47% to 8,083 shares [3]. - The stock has been active on the market, appearing on the "Dragon and Tiger List" twice this year, with the most recent instance on July 8, 2023, where it recorded a net buy of -7.94 million yuan [2]. Shareholder Composition - As of September 30, 2025, Fujilai's top ten circulating shareholders included a new entrant, Galaxy Kangle Stock A, holding 178,100 shares, representing a notable addition to the shareholder base [4]. Business Overview - Fujilai, established on November 27, 2000, and listed on March 29, 2022, specializes in the research, production, and sales of active pharmaceutical ingredients and health product raw materials. Its main revenue sources include products such as alpha-lipoic acid (66.02%), carnosine (14.86%), and others [2].

Core Viewpoint - The pharmaceutical and biotechnology industry is showing strong performance in Q3, with several companies reporting significant year-on-year growth in net profit, particularly in the traditional Chinese medicine sector and contract research organizations (CROs) [1][2][6]. Group 1: Company Performance - Over 50 pharmaceutical and biotechnology companies have disclosed their Q3 reports, with Teva Pharmaceutical, Fujilay, and Wohua Pharmaceutical leading in net profit growth rates of 985.18%, 430.16%, and 179.34% respectively [1][2]. - Teva Pharmaceutical reported a revenue of 692 million yuan, a 51.86% increase year-on-year, with net profit reaching 65.2 million yuan, up 985.18% [2]. - Wohua Pharmaceutical achieved a revenue of 625 million yuan, an 8.31% increase, with a net profit of 63.99 million yuan, reflecting a 179.34% growth [2]. Group 2: Industry Trends - The CRO and CDMO sectors are expected to continue their positive performance from the first half of the year, with several segments like traditional Chinese medicine, medical devices, and raw materials also showing good results [1][6]. - Companies like Mindray Medical anticipate a positive growth trajectory in both domestic and international markets, with expectations of improved revenue from Q3 onwards [4]. - The overall demand in the domestic pharmaceutical market is gradually recovering, particularly in early-stage research and development [5]. Group 3: Future Outlook - Analysts are optimistic about the innovation drug sector, which is expected to maintain high revenue growth and continue to reduce losses, with a focus on companies showing signs of performance improvement [6][7]. - The market is advised to pay attention to segments like medical devices and traditional Chinese medicine, which are projected to rebound in 2025 [7].